A surge in multi-billion dollar deals, led by Fifth Third's $11B acquisition of Comerica, signals a new wave of consolidation.
Zepzelca, in combination with Roche's Tecentriq, approved as first-line maintenance treatment for extensive-stage small cell lung cancer.
Regulator signals openness to an accelerated approval pathway for LX2006, a promising treatment for Friedreich's Ataxia cardiomyopathy.
FDA grants Breakthrough Therapy Designation for the company's treatment of Sanfilippo Syndrome, a rare neurodegenerative disorder.
FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
Mining equities like Argo Blockchain and Hive Digital are posting massive gains, outperforming Bitcoin as investors seek high-beta crypto exposure.